Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

Biophysical journal·2026
Same author

Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.

Research and practice in thrombosis and haemostasis·2026
Same author

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

ArXiv·2025
Same author

The kinetics and interplay of thrombin inhibition by 4 plasma proteinase inhibitors.

Blood vessels, thrombosis & hemostasis·2025
Same author

True anticoagulation safety cannot be achieved without better anticoagulants.

BMJ open quality·2025
Same author

Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions.

Journal of thrombosis and haemostasis : JTH·2025

Related Experiment Video

Updated: Jun 26, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

The coagulation cascade in cirrhosis.

Dougald M Monroe1, Maureane Hoffman2

  • 1Carolina Cardiovascular Biology Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Clinics in Liver Disease
|January 20, 2009
PubMed
Summary

Standard coagulation tests and models do not predict bleeding or clotting risks. Liver disease impairs the coagulation system's resilience, increasing risks of hemorrhage or thrombosis.

More Related Videos

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

Related Experiment Videos

Last Updated: Jun 26, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

Area of Science:

  • Biochemistry
  • Hematology
  • Pathophysiology

Background:

  • The coagulation cascade model explains prothrombin time (PT) and activated partial thromboplastin time (aPTT) test mechanisms.
  • However, PT and aPTT do not accurately reflect in vivo hemorrhage or thrombosis risk.
  • Hepatic insufficiency presents a complex hemostatic balance due to reduced pro- and anticoagulant proteins.

Purpose of the Study:

  • To evaluate the limitations of the coagulation cascade model and standard tests in predicting bleeding or clotting risks.
  • To understand the impact of hepatic insufficiency on the coagulation system's stability and response to insults.

Main Methods:

  • Review of existing literature on coagulation physiology and pathophysiology.
  • Analysis of the relationship between protein levels, thrombin generation, and clinical hemostatic risk in liver disease.

Main Results:

  • Coagulation tests and the cascade model do not reliably predict clinical bleeding or thrombosis.
  • In liver disease, a balanced reduction in coagulation factors does not significantly impair thrombin generation until critical levels are reached.
  • The coagulation system's ability to recover from stress is significantly reduced in hepatic insufficiency.

Conclusions:

  • The coagulation cascade model and associated tests have limitations in assessing real-world bleeding and clotting risks.
  • Liver disease compromises the coagulation system's compensatory capacity, leading to an increased susceptibility to both hemorrhage and thrombosis.